Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status Prescription
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 71052-212; 76055-0025; 76388-635; 72969-010; 50683-0384; 49452-1911; 43744-066
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.000278%Not Available
Circulatory collapse24.06.02.0010.000533%Not Available
Confusional state17.02.03.005; 19.13.01.0010.000533%
Cough22.02.03.0010.000799%
Cystitis20.03.02.002; 11.01.14.001--
Cytomegalovirus infection11.05.01.0020.000139%
Death08.04.01.001--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.0010.002398%
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.000139%Not Available
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.0020.002931%
Empyema11.01.08.0200.001066%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.0040.002931%
Feeling abnormal08.01.09.014--Not Available
Gamma-glutamyltransferase increased13.03.01.0110.000533%
Gastrooesophageal reflux disease07.02.02.0030.000799%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haematocrit decreased13.01.05.0010.000799%Not Available
Haemoglobin decreased13.01.05.0030.001066%Not Available
Haemolytic anaemia01.06.03.002--Not Available
Hallucination19.10.02.002--
Hepatic failure09.01.03.0020.000208%
Hepatitis09.01.07.0040.000533%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000533%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages